Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients.

Engels, Eric A; Jennings, Linda W; Everly, Matthew J; Landgren, Ola; Murata, Kazunori; Yanik, Elizabeth L; Pfeiffer, Ruth M; Onaca, Nicholas; Klintmalm, Goran B

Engels, Eric A; Jennings, Linda W; Everly, Matthew J; Landgren, Ola; Murata, Kazunori; Yanik, Elizabeth L; Pfeiffer, Ruth M; Onaca, Nicholas; Klintmalm, Goran B.

Afiliação

Engels EA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Jennings LW; Baylor Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.
Everly MJ; Terasaki Foundation Laboratory, Los Angeles, CA.
Landgren O; Memorial Sloan Kettering Cancer Center, New York, NY.
Murata K; Memorial Sloan Kettering Cancer Center, New York, NY.
Yanik EL; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Pfeiffer RM; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Onaca N; Baylor Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.
Klintmalm GB; Baylor Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.

Transplant Direct ; 4(6): e353, 2018 Jun.

Article em En | MEDLINE | ID: mdl-30123826

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google